ABT-199 (GDC-0199) 贮存: 储存温度-20°C 可溶性: •DMSO 100 mg/mL •Water <1 mg/mL •Ethanol <1 mg/mL 生化和生理学机理: ABT-199 (GDC-0199) ABT-199 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, currently in clinical trials. ABT-...
备注 ABT-199(GDC-0199) is aBcl-2-selective inhibitor withKiof<0.01 nM,>4800-fold more selective versus Bcl-xL and Bcl-w,and no activity to Mcl-1.Phase 2. 生化机理 ABT-199 is a potent and selective inhibitor of B-cell lymphoma-2(BCL-2) family proteins,currently in clinical trials....
Table 1 Single agent clinical trials of venetoclax/ABT-199 Full size table The latest update showed an ORR of 79 % in 84 patients with relapsed/refractory (R/R) CLL with median duration of response of 20.5 months. The most common adverse events (AEs) remained similar—neutropenia (39 %),...
生化机理 ABT-199 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, currently in clinical trials. ABT-199 inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lym...
备注 ABT-199(GDC-0199) is aBcl-2-selective inhibitor withKiof<0.01 nM,>4800-fold more selective versus Bcl-xL and Bcl-w,and no activity to Mcl-1.Phase 2. 生化机理 ABT-199 is a potent and selective inhibitor of B-cell lymphoma-2(BCL-2) family proteins,currently in clinical trials....
While ABT-737 has only been used for preclinical studies, ABT-263 has entered clinical trials for leukaemia and lymphoma. Results from these trials indicate some single agent activity of ABT-263 in CLL but, compared with the remarkable susceptibility of isolated primary CLL cells in vitro, the ...
199 that tightly binds to Bcl-2 but not Bcl-XL. Consistent with its lower affinity to Bcl-XL, ABT-199 spared human platelets both in vivo and in vitro. In clinical trials, ABT-199 exhibited immediate antileukemic activity after a single dose in three refractory CLL patients with only ...
ABT-199的适应症是接受常规化疗达到首次缓解的急性髓系白血病患者的维持治疗 此药物由AbbVie Inc./ AbbVie Ireland NL B.V./ 艾伯维医药贸易(上海)有限公司生产并提出实验申请,[实验的目的] 第1部分 在通过常规诱导和巩固化疗达到CR或CRi的AML患者中,确定使用venetoclax联合AZA作为维持治疗的RPTD。 第3部分 在通过...
Keywords: ABT-199; venetoclax; CYPs; drug transporters; drug–drug interaction 1. Introduction Venetoclax (ABT-199) is a specific oral B-cell lymphoma 2 (Bcl-2) inhibitor currently in clinical trials for the treatment of chronic lymphatic leukemia (CLL), acute myelogenous leukemia, small ...
Clinical Trial Information(data fromhttps://clinicaltrials.gov, updated on 2024-05-22) NCT NumberRecruitmentConditionsSponsor/CollaboratorsStart DatePhases NCT06382168Not yet recruiting Leukemia Myeloid Acute Delta-Fly Pharma Inc. May 31 2024Phase 1|Phase 2 ...